Philippe Charron
Philippe Charron is an expert in Cardiology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Philippe Charron in the top 1% of experts worldwide for Cardiomyopathies, Cardiomegaly and Aortic Valve Disease. Philippe Charron has authored 406 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 5 of them ongoing. SLR score: 1,476 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Genetics - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 406
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prognostic impact of pericardial effusion in patients with acute myocarditis. PMID 42670209 — pericardial effusion, cardiovascular diseases, phenotype, myocarditis, echocardiography | Eur Heart J Acute Cardiovasc Care | 2026 | 1 |
| A fully automated machine learning assisted pipeline to predict disease progression for early-stage hypertrophic cardiomyopathy from echocardiography. PMID 42609278 — disease progression, cardiomyopathy, hypertrophic, machine learning, diastole, echocardiography, learning, cardiomyopathies | Front Cardiovasc Med | 2026 | 0 |
| Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis. PMID 42506952 — heart failure, phenotype, prealbumin, amyloidosis, sex characteristics, sex, transthyretin amyloidosis, transthyretin cardiac amyloidosis, sex differences | JACC Heart Fail | 2026 | 0 |
| Cardiac and extracardiac outcomes after heart transplantation in laminopathies. PMID 42336625 — genes, laminopathies, mortality, heart diseases, heart, survival analysis, heart transplantation, transplants, transplantation | Heart | 2026 | 1 |
| Use of Disopyramide in Obstructive Hypertrophic Cardiomyopathy: A European Insight. PMID 42279095 — disopyramide, cardiomyopathy, hypertrophic, therapeutics, cardiomyopathies | J Clin Med | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy 2025-522553-19-00 — exercise, cardiomyopathy, dilated, safety, cardiomyopathies | Phase 2/Phase 3 | Recruiting | 2026 |
| LA HCM Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain A Randomized Multicenter Trial 2024-511084-28-00 — rivaroxaban, cardiomyopathy, hypertrophic, cardiomyopathies | Phase 3/Phase 4 | Recruiting | 2026 |
| Biological Collection for the Purpose of Exploring Genetic and Clinical biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy NCT07439952 — cardiomyopathy, hypertrophic, cytochrome p-450 cyp2c9, therapeutics, cytochrome p-450 cyp2c19, biological factors, cardiomyopathies | N/A | Not yet recruiting | 2026 |
| LA HCM Study Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain NCT07202897 — anticoagulants, stroke, rivaroxaban, cardiomyopathy, hypertrophic, therapeutics, cardiomyopathies | Phase 3 | Recruiting | 2026 |
| Modifying Factors in Striated Muscle Laminopathies NCT05394506 — muscular dystrophy, emery-dreifuss, cardiomyopathy, dilated, skin, genes, laminopathies, muscular dystrophies, muscles, myoblasts, lamins, autosomal emery-dreifuss muscular dystrophy, genes, modifier, biopsy, signs and symptoms, muscle, striated, sutures, fibroblasts, tissues, disinfection, deltoid muscle, mutation, temperature, cardiomyopathies, age of onset | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map